Sunday, March 1, 2009

BioAlliance Pharma reacquires the rights to Loramyc in Europe

February 27, 2009 _ BioAlliance Pharma SA, the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today announced the termination of the licensing agreement signed in 2007 with SpeBio.

The details can be read here.

No comments: